Specialty Drug Costs Should Be Left To Market-Based Solutions – PBMs
Executive Summary
CVS Caremark and Express Scripts agree that direct government involvement in pricing and coverage policies is not needed to contain the high cost of specialty drugs such as Gilead’s Sovaldi.
You may also be interested in...
Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
Medicare CED Not A Good Fit With Groundbreaking Products, Drug Firms Argue
In comments on CMS’ recent draft guidance on Medicare coverage with evidence development, Onyx Pharmaceuticals recommends that cutting edge therapies with postmarketing commitments like its cancer drug Kyprolis should be exempted, and Amyvid marketer Lilly says CED is not appropriate for radiopharmaceuticals.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.